PRV Reauthorization Strengthens Atossa Therapeutics' DMD Program

Congressional PRV extension underpins Atossa’s DMD program

WASHINGTON — Congress passes a five-year reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) program, a move that preserves Atossa Therapeutics’ eligibility to receive a voucher if the U.S. Food and Drug Administration approves (Z)-endoxifen for Duchenne muscular dystrophy (DMD). The PRV program applies to therapies for serious diseases primarily affecting patients from birth to age 18, and upon approval a qualifying product may generate a voucher that speeds review of a future application or can be sold or transferred. Disclosed PRV transactions in the past 18 months range between $150 million and $200 million, underscoring the potential non-dilutive value for developers.

Atossa, a clinical-stage biopharmaceutical company focused on oncology and other high-unmet-need areas, says the reauthorization validates the science behind (Z)-endoxifen — which received Rare Pediatric Disease designation late last year — and signals Congressional recognition of the costs and complexities of drug development. President and CEO Steven Quay, M.D., Ph.D., emphasizes the urgent need for alternatives to long-standing steroid treatment and to exon-specific or gene-targeted approaches that leave many patients with limited options. The company frames (Z)-endoxifen as a potential platform therapy with relevance across oncology and rare diseases, positioning the program as a strategic priority.

Senior Vice President of R&D Janet Rea, MSPH, highlights encouraging preclinical data and the drug’s ability to target DMD broadly because it does not depend on specific exon defects, which could allow application across a wider patient population. Rea references prior investigational new drug (IND) clearance pathways, citing the regulatory arc for therapies such as what becomes EXONDYS 51 (eteplirsen), as Atossa outlines plans to advance (Z)-endoxifen toward clinical testing in boys living with DMD. The company says it continues to prioritize safety and robust clinical data as it prepares for regulatory interactions.

Program optionality and partnering prospects

Atossa says the PRV reauthorization preserves optionality to accelerate development, engage potential partners and pursue regulatory interactions without immediate dilutive financing. Management frames the voucher as a strategic asset to support global collaboration and faster development timelines while maintaining focus on clinical validation.

Broader industry signal

The renewal of the PRV program sends a wider signal to rare pediatric disease developers by maintaining a high-value, non-dilutive incentive that can shift company strategy toward clinical advancement and partnership-led commercialization for therapies addressing unmet pediatric needs.